Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone as a Radiosensitizer in HNSCC
NCT06142318Phase 2Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Nov 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pirfenidone in head and neck squamous cell carcinoma (HNSCC), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Objective Response Rate at 1 month. Status: unknown.
02
Drugs
pirfenidone
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06142318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06142318.